Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

ABSTRACT

Increased platelet-leukocyte-aggregate (PLA) formation has been reported in acute coronary syndromes (ACS) and during cardiopulmonary bypass, and PLA formation has been acknowledged as a possible target for antiplatelet therapy in ACS and coronary interventions. It has also been suggested as a monitoring tool for risk stratification parameters. In a controlled study design as well as under clinical conditions we investigated the effect of antiplatelet agents by flow cytometric measurement of PLA formation. We were able to demonstrate considerable reduction in PLA formation under experimental and clinical clopidogrel therapy alone or in combination with aspirin. In healthy volunteers the percentage of monocyte-PLAs decreased significantly to 55 to 75% of the baseline under clopidogrel, depending on the type and concentration of the activating agent. In patients with severe peripheral artery disease, formation of monocyte-PLAs at baseline and after stimulation with thrombin receptor activating peptide (TRAP) or adenosine diphosphate (ADP) was significantly lower under combined therapy when compared with patients under aspirin alone or without antiplatelet treatment.

Flow cytometric measurement of PLA formation appears to be well suited for dose response of antiplatelet agents in healthy volunteers and a valuable tool in establishing the clinical significance of circulating PLAs. It may also be a qualified method to monitor platelet function in long-term treatment with antiplatelet agents that interfere with the degranulation process. It is not suited for acute situations.

Platelet-leukocyte-aggregates - flow cytometry - clopidogrel dose response - PAOD patients

REFERENCES

• 1 Neumann F J, Marx N, Gawaz M et al.. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets.  Circulation. 1997;  95 2387-2394
• 2 Ott I, Neumann F J, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina.  Circulation. 1996;  94 1239-1246
• 3 Barry O P, Pratico D, Savani R C, FitzGerald G A. Modulation of monocyte-endothelial cell interactions by platelet microparticles.  J Clin Invest. 1998;  102 136-144
• 4 Nagata K, Tsuji T, Todoroki N et al.. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62).  J Immunol. 1993;  151 3267-3273
• 5 Ross R. Atherosclerosis: an inflammatory disease.  N Engl J Med. 1999;  340 115-126
• 6 Furman M I, Benoit S E, Barnard M R et al.. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.  J Am Coll Cardiol. 1998;  31 352-358
• 7 Ott I, Neumann F J, Kenngott S, Gawaz M, Schomig A. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction.  Am J Cardiol. 1998;  82 938-942
• 8 Rinder C S, Bonan J L, Rinder H M, Mathew J, Hines R, Smith B R. Cardiopulmonary bypass induces leukocyte-platelet adhesion.  Blood. 1992;  79 1201-1205
• 9 Zahler S. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass.  Cardiovasc Res. 1999;  41 722-730
• 10 Michelson A D, Barnard M R, Krueger L A, Valeri C R, Furman M I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction.  Circulation. 2001;  104 1533-1537
• 11 Entman M L, Ballantyne C M. Association of neutrophils with platelet aggregates in unstable angina. Should we alter therapy?.  Circulation. 1996;  94 1206-1208
• 12 Furman M I, Barnard M R, Krueger L A et al.. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.  J Am Coll Cardiol. 2001;  38 1002-1006
• 13 Sarma J, Laan C A, Alam S, Jha A, Fox K A, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes.  Circulation. 2002;  105 2166-2171
• 14 Neumann F J, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.  J Am Coll Cardiol. 1999;  34 1420-1426
• 15 May A E, Neumann F J, Gawaz M, Ott I, Walter H, Schomig A. Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation.  Eur Heart J. 1997;  18 1913-1920
• 16 Klinkhardt U, Graff J, Harder S. Clopidogrel but not abciximab reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.  Clin Pharmacol Ther. 2002;  71 176-185
• 17 Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.  Clin Pharmacol Ther. 2003;  73 232-241
• 18 Phipps R P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.  Proc Natl Acad Sci USA. 2000;  97 6930-6932
• 19 Heeschen C, Dimmeler S, Hamm C W et al.. CAPTURE Study Investigators . Soluble CD40 ligand in acute coronary syndromes.  N Engl J Med. 2003;  348 1104-1111